Ascentage Pharma Corp (AAPG) Net Margin

Ascentage Pharma (AAPG) - corporate logo

Unique apoptosis patents and massive R&D investments create a powerful defensive barrier for Ascentage Pharma Group (AAPG). Net profit returns from sales confirm this potential, where -229.30 serves as the current metric level. However, uncertainty regarding test outcomes and a shortage of funds create threats. Success depends on drug approvals in the US and China under strict FDA supervision.

AAPG: Ascentage Pharma Corp Company Net Profitability 01/25/2025 - 11/19/2026

Metric breakdowns and analytics for Ascentage (AAPG)

Comprehensive company analysis:Ascentage Pharma, AAPG
Flagship merchandise of Ascentage Pharma Group International

The scale of innovative cancer drug development led by Yan Dapin at Ascentage Pharma Group (AAPG) requires colossal expenditures, making net profit margin a key indicator of capital management efficiency. This metric is calculated as the share of final profit in total revenue, allowing investors to assess the business's ability to convert operational successes into real cash flow and confirm the asset's stability.

Who Ascentage Pharma Group competes with

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales CGON (CG Oncology Corp)|Net Margin UroGen Pharma (URGN)|Net Sales Margin Bicara Therapeutics (BCAX)|Net Sales Margin PSNL (personalis.com)|Net Profit Rate ERAS|DCTH: Return on Sales by Net Profit|YmAbs - Company Net Profitability|aurabiosciences.com (AURA) - Net Margin|Candel Therapeutics Inc. - Net Profit Rate|Net Margin Accuray Inc.|Net Margin SELLAS Life Sciences Group SLS|Net Sales Margin ACTU|CTOR - Net Margin|Net Sales Margin HURA (TuHURA Biosciences, Inc.)|Net Profit Rate TARA|FATE: Return on Sales by Net Profit|WHWK (aadibio.com) - Net Return on Sales|TCRX (TScan Therapeutics, Inc.) - Return on Sales by Net Profit|Net Margin Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Net Sales Margin|CVM (CEL-SCI Corporation) - Company Net Profitability|Net Sales Margin OSTX|Net Sales Margin Radiopharm Theranostics Ltd (RADX)|Net Sales Margin ARTV (Artiva Biotherapeutics)|Net Sales Margin Adlai Nortye Ltd. ANL|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)